Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CURTIS A PETTAWAY and PATRICIA TRONCOSO.
Connection Strength

2.306
  1. The ratio of matrix metalloproteinase to E-cadherin expression: a pilot study to assess mRNA and protein expression among African American prostate cancer patients. Prostate. 2008 Sep 15; 68(13):1467-76.
    View in: PubMed
    Score: 0.339
  2. A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. Prostate. 2024 May; 84(7):694-705.
    View in: PubMed
    Score: 0.248
  3. The association of body mass index with tumor aggression among men undergoing radical prostatectomy. Urol Oncol. 2024 04; 42(4):116.e1-116.e7.
    View in: PubMed
    Score: 0.246
  4. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment. Hum Pathol. 2017 06; 64:186-190.
    View in: PubMed
    Score: 0.152
  5. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93.
    View in: PubMed
    Score: 0.143
  6. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8.
    View in: PubMed
    Score: 0.091
  7. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int. 2007 Jul; 100(1):63-9.
    View in: PubMed
    Score: 0.078
  8. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer. 2006 Jul 01; 107(1):75-82.
    View in: PubMed
    Score: 0.073
  9. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6889-94.
    View in: PubMed
    Score: 0.069
  10. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate. 2005 Jun 15; 64(1):40-9.
    View in: PubMed
    Score: 0.068
  11. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res. 2003 Jun; 9(6):2185-94.
    View in: PubMed
    Score: 0.059
  12. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).
    View in: PubMed
    Score: 0.058
  13. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res. 2000 Jun; 6(6):2295-308.
    View in: PubMed
    Score: 0.048
  14. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol. 2000 Mar; 18(5):1050-7.
    View in: PubMed
    Score: 0.047
  15. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97.
    View in: PubMed
    Score: 0.046
  16. A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer. J Urol. 1999 Feb; 161(2):509-14.
    View in: PubMed
    Score: 0.044
  17. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998 Aug; 160(2):437-42.
    View in: PubMed
    Score: 0.042
  18. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76.
    View in: PubMed
    Score: 0.039
  19. Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men. Prostate. 2017 Jul; 77(10):1118-1127.
    View in: PubMed
    Score: 0.039
  20. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
    View in: PubMed
    Score: 0.038
  21. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun. 2016 05 31; 7:11674.
    View in: PubMed
    Score: 0.036
  22. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76.
    View in: PubMed
    Score: 0.034
  23. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2015 Sep; 18(3):276-80.
    View in: PubMed
    Score: 0.034
  24. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate. 2013 Jan; 73(2):153-61.
    View in: PubMed
    Score: 0.028
  25. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81.
    View in: PubMed
    Score: 0.026
  26. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010 Nov 02; 10:599.
    View in: PubMed
    Score: 0.025
  27. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20.
    View in: PubMed
    Score: 0.022
  28. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34.
    View in: PubMed
    Score: 0.022
  29. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009 May; 55(5):1135-43.
    View in: PubMed
    Score: 0.021
  30. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31.
    View in: PubMed
    Score: 0.019
  31. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702.
    View in: PubMed
    Score: 0.017
  32. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate. 2004 Sep 01; 60(4):343-51.
    View in: PubMed
    Score: 0.016
  33. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2587-93.
    View in: PubMed
    Score: 0.016
  34. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 2002 May 15; 94(10):2610-7.
    View in: PubMed
    Score: 0.014
  35. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. Prostate Cancer Prostatic Dis. 1999 Nov; 2(S3):S27.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.